Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial

BACKGROUND: We performed a cost-effectiveness analysis of trastuzumab plus chemotherapy for human epidermal growth factor type-2 (HER2)-positive advanced gastric cancer (GC) based on data obtained from the Trastuzumab for Gastric Cancer (ToGA) trial from a Japanese perspective. METHODS: The followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiroiwa, T, Fukuda, T, Shimozuma, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241558/
https://www.ncbi.nlm.nih.gov/pubmed/21959871
http://dx.doi.org/10.1038/bjc.2011.390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241558/
https://www.ncbi.nlm.nih.gov/pubmed/21959871
http://dx.doi.org/10.1038/bjc.2011.390

Ejemplares similares